Gwenn Hansen

Company: Nurix Therapeutics, Inc.

Job title: Chief Scientific Officer

Seminars:

Targeted Protein Degraders as Next Generation Antibody Payloads 1:40 pm

Introducing Nurix’s expertise in targeted protein degradation and degrader-antibody conjugates Discussing the advantages of using degraders as antibody payloads  Exploring collaborationsRead more

day: Conference Day 2

Panel Discussion: Where do DACs Fit in? Discussing the Decision to Think about Degraders as Payloads 2:20 pm

• What is it about small molecule degraders that lend themselves to making good payloads? • Sharing parameters that allow a degrader protein to be distinct from a toxic payload • What are some good targets for DACs? • Collaboration potential between antibody engineering and protein degradation companiesRead more

day: Conference Day 2